Phase 1 Study With Expansion Cohorts to Assess the Safety, Tolerability, and Activity of Oraxol (Paclitaxel + HM30181A) in Combination With Pembrolizumab in Subjects With Advanced Solid Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 17 Jan 2019
Price : $35 *
At a glance
- Drugs HM 30181A (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Athenex
- 08 Jan 2019 Planned primary completion date changed from 30 Jul 2020 to 30 Oct 2020.
- 08 Jan 2019 Status changed from not yet recruiting to recruiting.
- 26 Nov 2018 According to Athenex media release, company initiates this study.